Skip to content

Study · In vitro (cells) · 2014

3 results

Niacin receptor activation improves human microvascular endothelial cell angiogenic function during lipotoxicity.

Hughes-Large JM, Pang DK, Robson DL, Chan P, Toma J, Borradaile NM

Atherosclerosis28 Oct 2014Cited by 26 (Europe PMC)

PMID25463108 (opens in a new tab)DOI10.1016/j.atherosclerosis.2014.10.090 (opens in a new tab)PepBankPUB-25463108
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In human microvascular endothelial cells under palmitate overload, NMN improved tube formation.

    In plain wordsIn cells exposed to excess palmitate, NMN improved tube formation.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseTube formation
    Study

    humann: not reported in source

    Human microvascular endothelial cells under palmitate overload
    Outcome group
    Wound healing · Cardiovascular
    Studied dose
    1 μMAs given in this study (human).

    Source sentences

    Summary
    Although both niacin and NMN improved HMVEC tube formation during palmitate overload, only NMN increased cellular NAD(+) and SIRT1 activity.
    1 context sentence
    Summary · context
    Angiogenic function in excess palmitate was assessed by tube formation following treatment of human microvascular endothelial cells (HMVEC) with either a relatively low concentration of niacin (10 μM), or nicotinamide mononucleotide (NMN) (1 μM), a direct NAD(+) precursor.
  2. 02LabIn vitro (cells)Mechanism

    In human microvascular endothelial cells, NMN increased cellular NAD+ during palmitate overload.

    In plain wordsIn cells exposed to excess palmitate, NMN increased cellular NAD+.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseCellular NAD+
    Study

    humann: not reported in source

    Human microvascular endothelial cells under palmitate overload
    Outcome group
    Receptor activity and mechanism · Metabolic and weight
    Studied dose
    1 μMAs given in this study (human).

    Source sentences

    Summary
    Although both niacin and NMN improved HMVEC tube formation during palmitate overload, only NMN increased cellular NAD(+) and SIRT1 activity.
    1 context sentence
    Summary · context
    Angiogenic function in excess palmitate was assessed by tube formation following treatment of human microvascular endothelial cells (HMVEC) with either a relatively low concentration of niacin (10 μM), or nicotinamide mononucleotide (NMN) (1 μM), a direct NAD(+) precursor.
  3. 03LabIn vitro (cells)Mechanism

    In human microvascular endothelial cells, NMN increased SIRT1 activity during palmitate overload.

    In plain wordsIn cells exposed to excess palmitate, NMN increased SIRT1 activity.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseSIRT1 activity
    Study

    humann: not reported in source

    Human microvascular endothelial cells under palmitate overload
    Outcome group
    Receptor activity and mechanism · Metabolic and weight
    Studied dose
    1 μMAs given in this study (human).

    Source sentences

    Summary
    Although both niacin and NMN improved HMVEC tube formation during palmitate overload, only NMN increased cellular NAD(+) and SIRT1 activity.
    1 context sentence
    Summary · context
    Angiogenic function in excess palmitate was assessed by tube formation following treatment of human microvascular endothelial cells (HMVEC) with either a relatively low concentration of niacin (10 μM), or nicotinamide mononucleotide (NMN) (1 μM), a direct NAD(+) precursor.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.